StockNews.com Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Hold

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other analysts also recently commented on the company. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Barrington Research upped their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Oppenheimer reissued an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Stock Up 0.4 %

Shares of LMAT opened at $100.69 on Friday. The firm has a market capitalization of $2.26 billion, a PE ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. The firm has a 50-day moving average price of $97.65 and a 200 day moving average price of $89.54. LeMaitre Vascular has a 52-week low of $52.88 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period last year, the firm posted $0.33 earnings per share. The business’s revenue was up 15.6% on a year-over-year basis. On average, equities analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in the stock. NBC Securities Inc. increased its stake in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the period. USA Financial Formulas purchased a new position in shares of LeMaitre Vascular during the 3rd quarter valued at $60,000. West Oak Capital LLC acquired a new position in shares of LeMaitre Vascular in the second quarter worth $58,000. GAMMA Investing LLC raised its holdings in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares in the last quarter. Finally, nVerses Capital LLC boosted its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.